Tru-D SmartUVC to Exhibit and Sponsor Pre-Conference at the APIC 2015 Annual Conference
MEMPHIS, Tenn., June 24, 2015 /PRNewswire/ -- Tru-D SmartUVC LLC will return to the APIC 2015 Annual Conference to demonstrate the UV disinfection robot's one-of-a-kind technology and newest innovations, as well as sponsor the pre-conference workshop "Disinfection, Sterilization, and Antisepsis: Principles, Practices, Current Issues, New Research, and New Technologies." Tru-D SmartUVC will be exhibiting in booth 1414 from June 27 to 29.
Logo - http://photos.prnewswire.com/prnh/20150624/225353LOGO
Featuring William A. Rutala, MS, MPH, Ph.D., CIC, a premier scientific authority in the field of UV disinfection research, the pre-conference program will present scientific and practical information related to the use of sterilization technologies and environmental disinfectants in health care settings, specifically about the importance of selecting the correct automated UV disinfection system for optimal results. Additionally, the international symposium will include lectures and panel discussions on the latest breakthroughs regarding cleaning and disinfecting of environmental surfaces. Other presenters include Michelle J. Alfa, Ph.D.; Elaine Larson, RN, Ph.D.; Rose E. Seavey RN, BS, MBA, CNOR, CRST, SSPDT; Craig A. Wallis; David J. Weber, M.D., MPH; Emily E. Sickbert-Bennett, Ph.D.; Judie Bringhurst, MS; Charles P. Gerba, Ph.D.; and Curtis J. Donsky, M.D. Tru-D SmartUVC LLC is one of the main sponsors of this event.
The ECRI Institute named disinfecting robots as the No. 1 technology in the Top 10 Hospital C-Suite Watch List for 2015. And, by no coincidence, the highly anticipated results of the most comprehensive UV disinfection study to date, Benefits of Enhanced Terminal Room Disinfection performed by the Duke Infection Control Outreach Network, are due out later this year and are expected to be a major topic of the UV disinfection conversation at APIC 2015. Tru-D's exclusive selection in the $2 Million study, which was funded by the Centers for Disease Prevention and Control, resulted in an epidemiologically correct double-blind data pool inclusive of 25,000 room disinfection cycles and 100,000 patient days in 10 hospitals of varying size and census. This vast data pool allowed for the exclusion of confounding factors and conflicts of interest related to the current literature available, making the real-world results of this study the first of its kind.
"In regards to UV disinfection, hospitals demand more than just delivering consistent outcomes – they want the data to prove it," said Chuck Dunn, president of Tru-D SmartUVC LLC. "Hospitals are insisting on solid reporting data that integrates into software found in environmental services and bed tracking software packages. Tru-D SmartUVC's built-in sensor technology ensures consistent outcomes through measurable dose delivery, but the device's cloud-based usage tracking device provides hospitals with the data they need for this integration."
Tru-D SmartUVC is the world leader in disinfection systems with its patented method of delivering an automated measured dose of germicidal UVC to consistently disinfect an entire room during a single cycle. Tru-D operates from a single position within the room, ensuring 99.99 percent pathogen reduction in direct and shadowed areas and eliminating the threat of human error in the disinfection process. Additionally, the robot's cloud-based data-tracking technology, iTru-D, transfers usage data to a customized portal to provide real-time results through concise graphics and exportable records. Validated in more than 12 independent studies, Tru-D's combined automated measured dosing capabilities and real-time usage-tracking features make Tru-D the most precise and advanced automated UV disinfection system available.
About Tru-D SmartUVC
Tru-D SmartUVC is the device of choice for nearly all of the existing independent research on UV disinfection technology. More than 300 Tru-Ds have been deployed to disinfect hospitals across the globe, including the National Institutes of Health Clinical Center in Bethesda, Maryland; Vancouver General Hospital in Vancouver, British Columbia; Nottingham University Hospitals NHS Trust's QMC campus in Nottingham, England; and Ebola Treatment Units at ELWA Hospital and Island Hospital in Monrovia, Liberia. For information and links to independent studies on Tru-D, visit http://www.Tru-D.com.
For more information, contact:
Ali Glemser
Obsidian Public Relations
Phone: 901-572-1042
Email
SOURCE Tru-D SmartUVC
Share this article